Testicular Cancer and the Hormones It Disturbs
Blood tests for testicular cancer look for telltale proteins and enzymes that tumors release into the bloodstream. These markers function as real-time signals of tumor activity, helping may support clinical assessment of the diagnosis, estimate how much cancer is present, guide treatment choices, and monitor response or relapse over time. The key markers are alpha-fetoprotein (AFP), a fetal protein produced by certain germ cell tumor cells; human chorionic gonadotropin (hCG), a hormone made by tumor cells that mimic placental tissue; and lactate dehydrogenase (LDH), an enzyme that rises with rapid cell turnover and tumor burden. Because these substances are made by the cancer itself—or by cells it imitates—shifts in their levels mirror what the tumor is doing inside the body: growing, quieting down with therapy, or returning. Biomarkers complement the physical exam and imaging, offering a quick, repeatable window into tumor biology between scans. In short, testicular cancer biomarkers provide a practical, biologically grounded readout that helps personalize care.
Why Testosterone and Estradiol Get Tracked in Testicular Cancer
Blood tests for testicular cancer look for tumor markers that mirror what the tumor is doing and how the body is responding. Alpha‑fetoprotein (AFP), beta‑human chorionic gonadotropin (β‑hCG), and lactate dehydrogenase (LDH) signal tumor presence, growth rate, and tissue stress. At the same time, sex hormones like testosterone and estradiol reveal how the testes and pituitary–gonadal axis are functioning, which matters for energy, mood, fertility, bone, and metabolic health.In healthy males, AFP and β‑hCG are undetectable or very low, and LDH sits within the lab’s normal band. Adult male testosterone typically spans roughly 300–1000, with well‑being often helps assess in the middle to upper half. Estradiol in men is usually in the low tens, with optimal effects commonly in the low‑to‑mid portion of its range.When these values are low, undetectable AFP and β‑hCG suggest no active germ‑cell tumor or successful treatment. Low testosterone, often from testicular damage, surgery, or chemotherapy, reflects underactive Leydig cells and can bring fatigue, low libido, depressed mood, decreased muscle, anemia, and bone loss; low estradiol follows from low testosterone and can worsen bone and sexual symptoms. In adolescent boys, low testosterone can delay puberty and stunt growth.When values run high, elevated AFP or β‑hCG points to active tumor, helps distinguish subtypes (AFP is not produced by pure seminoma), and can flag recurrence earlier than imaging. High β‑hCG can drive breast tenderness or enlargement and suppress pituitary signals, lowering native testosterone; estradiol may rise via aromatization, amplifying these effects. LDH often tracks overall tumor burden.Big picture, these markers connect a testicular tumor to whole‑body physiology—cell turnover, endocrine balance, fertility, and bone–metabolic health—and, when trended over time, they sharpen diagnosis, staging, response assessment, and long‑term risk monitoring.
What Hormone Labs Reveal in Testicular Cancer Care
Testicular cancer blood testing provides insight into how the body’s reproductive and endocrine systems are functioning, which has ripple effects on energy, metabolism, muscle mass, mood, and fertility. At Superpower, we focus on two key hormones—estradiol and testosterone—because they are central to testicular health and can reveal important information about the presence or impact of testicular cancer.Estradiol and testosterone are both steroid hormones produced primarily in the testes. Testosterone is the main male sex hormone, essential for sperm production, muscle strength, bone density, and overall vitality. Estradiol, though present in smaller amounts in men, is also produced in the testes and plays a role in bone health, brain function, and modulating the effects of testosterone. In the context of testicular cancer, abnormal levels of these hormones can signal disruption of normal testicular function, either from the tumor itself or as a result of treatment.Stable and healthy levels of estradiol and testosterone suggest that the testes are functioning well, supporting reproductive health, physical performance, and emotional stability. When these hormones are out of balance, it may indicate that the cancer is affecting hormone production, which can impact fertility, energy, and overall well-being.Interpretation of estradiol and testosterone levels must consider factors such as age, recent illness, medications, and the specific laboratory methods used. Hormone levels naturally fluctuate and can be influenced by non-cancerous conditions, so results are always interpreted in the context of the individual’s overall health and clinical picture.
FAQs
It is a blood check that looks for signals of testicular tumor activity and testicular hormone function. In clinical care, tumor markers such as alpha‑fetoprotein (AFP), beta‑hCG, and LDH help assess germ cell tumors. Superpower measures Estradiol and Testosterone to show how well your testes are producing sex hormones (Leydig cell function) and whether estrogen–androgen balance is shifted. Abnormal hormones can accompany some testicular tumors or other testicular disorders, but hormones alone cannot diagnose or exclude cancer.
It helps clarify what your testes are doing biologically. Tumor markers (AFP, beta‑hCG, LDH) can reflect tumor burden and response to therapy. Estradiol and Testosterone from Superpower reveal endocrine effects of testicular disease, such as low androgen output (hypogonadism) or excess estrogen exposure (hyperestrogenemia). Together, these data add context to symptoms or imaging and help track physiology during evaluation or follow‑up.
Yes. With Superpower, our team member can organise a blood draw in your home.
There is no routine schedule for the general population. Timing depends on context. During evaluation of a testicular concern, repeat measurements may be used to confirm patterns and track change. After a confirmed testicular cancer, tumor markers are tested at clinician‑defined intervals for surveillance. For hormones (Estradiol, Testosterone), repeating morning tests on separate days improves reliability due to natural day‑to‑day and diurnal variation.
Time of day, age, acute illness, stress, and recent strenuous exercise shift hormones. Medications and substances (testosterone therapy, anabolic steroids, opioids, glucocorticoids, alcohol, biotin supplements) can alter results or assays. Obesity, liver, kidney, and thyroid disease change Estradiol and Testosterone metabolism. For tumor markers, liver disease can raise AFP, and many noncancer conditions can elevate LDH. Hemolysis and lab handling also influence values.
Yes. Test in the morning (ideally before 10 a.m.) and use the same timing for repeats. Avoid heavy exercise and alcohol for 24 hours beforehand. If possible, avoid high‑dose biotin for 24–48 hours to prevent assay interference. Fasting 8–12 hours can reduce variability for Testosterone. Take usual prescriptions unless told otherwise, and tell us about hormones or supplements.
References
- Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018). Testicular cancer. Nature Reviews Disease Primers, 4(1), 29. https://doi.org/10.1038/s41572-018-0029-0
- Rajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A. S., & Bokemeyer, C. (2016). Testicular germ cell tumours. Lancet, 387(10029), 1762-1774. https://doi.org/10.1016/S0140-6736(15)00991-5
- Gilligan, T. D., Seidenfeld, J., Basch, E. M., Einhorn, L. H., Fancher, T., Smith, D. C., Stephenson, A. J., Vaughn, D. J., Cosby, R., & Hayes, D. F. (2010). American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. Journal of Clinical Oncology, 28(20), 3388-3404. https://doi.org/10.1200/JCO.2009.26.4481
- National Cancer Institute. (2024). Testicular cancer treatment (PDQ)-Patient version. https://www.cancer.gov/types/testicular/patient/testicular-treatment-pdq
- La Vignera, S., Cannarella, R., Duca, Y., Barbagallo, F., Burgio, G., Compagnone, M., Di Cataldo, A., Calogero, A. E., & Condorelli, R. A. (2019). Hypogonadism and sexual dysfunction in testicular tumor survivors: A systematic review. Frontiers in Endocrinology, 10, 264. https://doi.org/10.3389/fendo.2019.00264






































.avif)
